The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
TACE for patients with renal carcinoma and the influence on cell immune function
Author(s): 
Pages: 121-123
Year: Issue:  2
Journal: Acta Academiae Medicinae Shandong

Keyword:  Renal cell carcinomaRenal arteryChemoembolizationCell immune;
Abstract: 目的探讨经肾动脉选择性化疗栓塞(TACE)治疗肾细胞癌的疗效及其对细胞免疫功能的影响。方法29例肾癌患者,均经TACE治疗,于治疗前、治疗后2周、4周,观测外周血CD3+、CD4+、CD8+、CD4+/CD8+、NK的变化,并进行统计学分析。结果与术前比较,TACE治疗后2周,CD3+,、CD4+、CD4+/CD8+及NK降低,CD8+升高(P均<0.01)。TACE后4周恢复至术前水平,其中CD4+值较术前升高(P<0.01),CD3+,、CD4+/CD8+及CD8+与术前比较,差异无统计学意义(P>0.05)。术后2周与4周各组数值差异有统计学意义(P<0.01)。术前血尿、腰疼等症状逐渐缓解至完全消失;术前肿瘤平均最大直径为(12.335±2.072)cm,术后3040 d复查,平均缩小(3.025±1.1 849)cm(P<0.01)。结论TACE治疗肾癌安全、有效,但短期内对机体免疫功能有一定抑制作用。因此在TACE治疗同时,应辅以免疫增强治疗。
Related Articles
No related articles found